Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients

Kalijn F Bol; Hanneke W Mensink; Erik H J G Aarntzen; Gerty Schreibelt; Jan E E Keunen; Pierre G Coulie; Annelies de Klein; Cornelis J A Punt; Dion Paridaens; Carl G Figdor; I Jolanda M de Vries

doi:10.1016/j.ajo.2014.07.014

Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients

Kalijn F Bol, Hanneke W Mensink, Erik H J G Aarntzen, Gerty Schreibelt, Jan E E Keunen, Pierre G Coulie, Annelies de Klein, Cornelis J A Punt, Dion Paridaens, Carl G Figdor, I Jolanda M de Vries

Research output: Contribution to journal › Article › Research › peer-review

Abstract

PURPOSE: To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma.

DESIGN: Interventional case series.

METHODS: We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival.

RESULTS: Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed.

CONCLUSIONS: Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma.

Original language	English
Pages (from-to)	939-47
Number of pages	9
Journal	American Journal of Ophthalmology
Volume	158
Issue number	5
DOIs	https://doi.org/10.1016/j.ajo.2014.07.014
Publication status	Published - Nov 2014

Keywords

Cancer Vaccines/therapeutic use
Dendritic Cells/immunology
Follow-Up Studies
Humans
Melanoma/mortality
Neoplasm Metastasis
Netherlands/epidemiology
Prospective Studies
Survival Rate/trends
Time Factors
Uveal Neoplasms/mortality
Vaccination/methods
gp100 Melanoma Antigen/immunology

Access to Document

10.1016/j.ajo.2014.07.014

Cite this

Bol, K. F., Mensink, H. W., Aarntzen, E. H. J. G., Schreibelt, G., Keunen, J. E. E., Coulie, P. G., de Klein, A., Punt, C. J. A., Paridaens, D., Figdor, C. G., & de Vries, I. J. M. (2014). Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. American Journal of Ophthalmology, 158(5), 939-47. https://doi.org/10.1016/j.ajo.2014.07.014

@article{de72d780c5bc4e56ba665817ffee435f,

title = "Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients",

abstract = "PURPOSE: To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma.DESIGN: Interventional case series.METHODS: We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival.RESULTS: Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed.CONCLUSIONS: Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma.",

keywords = "Cancer Vaccines/therapeutic use, Dendritic Cells/immunology, Follow-Up Studies, Humans, Melanoma/mortality, Neoplasm Metastasis, Netherlands/epidemiology, Prospective Studies, Survival Rate/trends, Time Factors, Uveal Neoplasms/mortality, Vaccination/methods, gp100 Melanoma Antigen/immunology",

author = "Bol, {Kalijn F} and Mensink, {Hanneke W} and Aarntzen, {Erik H J G} and Gerty Schreibelt and Keunen, {Jan E E} and Coulie, {Pierre G} and {de Klein}, Annelies and Punt, {Cornelis J A} and Dion Paridaens and Figdor, {Carl G} and {de Vries}, {I Jolanda M}",

year = "2014",

month = nov,

doi = "10.1016/j.ajo.2014.07.014",

language = "English",

volume = "158",

pages = "939--47",

number = "5",

}

TY - JOUR

T1 - Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients

AU - Bol, Kalijn F

AU - Mensink, Hanneke W

AU - Aarntzen, Erik H J G

AU - Schreibelt, Gerty

AU - Keunen, Jan E E

AU - Coulie, Pierre G

AU - de Klein, Annelies

AU - Punt, Cornelis J A

AU - Paridaens, Dion

AU - Figdor, Carl G

AU - de Vries, I Jolanda M

PY - 2014/11

Y1 - 2014/11

N2 - PURPOSE: To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma.DESIGN: Interventional case series.METHODS: We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival.RESULTS: Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed.CONCLUSIONS: Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma.

AB - PURPOSE: To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma.DESIGN: Interventional case series.METHODS: We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival.RESULTS: Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed.CONCLUSIONS: Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma.

KW - Cancer Vaccines/therapeutic use

KW - Dendritic Cells/immunology

KW - Follow-Up Studies

KW - Humans

KW - Melanoma/mortality

KW - Neoplasm Metastasis

KW - Netherlands/epidemiology

KW - Prospective Studies

KW - Survival Rate/trends

KW - Time Factors

KW - Uveal Neoplasms/mortality

KW - Vaccination/methods

KW - gp100 Melanoma Antigen/immunology

U2 - 10.1016/j.ajo.2014.07.014

DO - 10.1016/j.ajo.2014.07.014

M3 - Article

C2 - 25038326

SN - 0002-9394

VL - 158

SP - 939

EP - 947

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

IS - 5

ER -

Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this